PYXSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Pyxis Oncology, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$1.76+0.08 (+4.76%)

Close on Oct 19, 2026

Market cap: $112.63M
P/E (TTM): –
Dividend yield: –

Pyxis Oncology, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	14	16	–	–	–	–
Cost of Revenue	2.39	0.48	–	–	–	–
Gross Profit	11	16	–	–	–	–
Research & Development	74	59	50	86	51	9.05
General & Administrative	22	25	33	37	19	3.85
Operating Expenses	–	–	82	123	70	13
Operating Income	-84	-89	-82	-123	-70	-13
Interest & Investment Income	0.65	0.93	1.84	2.76	0.02	0.07
Income from Equity Investments	–	–	–	0	-0.23	–
Other Non-Operating Income	6.19	9.97	8.41	2.76	-6.03	0.07
Pretax Income	-78	-79	-74	–	–	–
Income Tax Expense	1.39	-2.16	–	–	–	–
Net Income incl. Noncontrolling Interests	-80	-77	-74	-121	-76	-13
Net Income	-80	-77	-74	-121	-76	-13
EPS (Basic)(per share)	-1.28	-1.32	-1.85	-3.65	-8.95	-12.45
EPS (Diluted)(per share)	-1.28	-1.32	-1.85	-3.65	-8.95	-12.45
Shares Outstanding (Basic, Weighted)(shares)	62	58	40	33	8.49	1.03
Shares Outstanding (Diluted, Weighted)(shares)	62	58	40	33	8.49	1.03
EBITDA	-80	-86	-80	-123	-69	-12

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: 82.8%
Operating margin: -664.6%
Net margin: -640.3%
Return on equity, FY2025: -91.4%

Financial strength

Current ratio: 1.34
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 68.6%

Valuation

P/E ratio: –
Price to sales: 8.13
Price to book: 9.84
Dividend yield: –